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ABSTRACT
Objective: To assess the impact of inappropriate antimicrobial treatment on the 30-day mortality in patients with Aci-
netobacter baumannii associated infections.
Methods: 87 patients with nosocomial infections caused by A. baumannii were included in the study. Among them 39 
patients had favorable outcome, while 48 patients died within 30 days after pathogen isolation. In order to assess the 
impact of antimicrobial therapy on outcomes, the cases with appropriate antimicrobial treatment from both studied 
groups were compared with the cases in which patient’s received inappropriate therapy. The Chi-square or Z-test was 
used to assess differences in categorical variables. Continuous variables were compared using the Mann-Whitney test. 
Results: Among patients with favorable outcomes four people received appropriate empirical antimicrobial treatment, 
while in the other group only three patients. The odds ratio was 1.7 (95% CI 0.4-8.2; p=0.77). Appropriate antimicrobial 
agents were administered as a part of causal treatment to 27 patients who survived and to 11 patients who died within 
30 days after pathogen isolation. The odds ratio was 6.7 (95% CI 2.6-17.3; p<0.001).
Conclusion: Our study has revealed that appropriate causal antimicrobial therapy decreases 30-day mortality rate in 
patients with nosocomial infections caused by A. baumannii . J Microbiol Infect Dis 2013;3(4): 163-168
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Acinetobacter baumannii ilişkili enfeksiyonları olan hastalarda uygun antimikrobiyal 
tedavinin sağkalım üzerine etkisi
ÖZET
Amaç: Acinetobacter baumannii ilişkili enfeksiyonları olan hastalarda uygunsuz antimikrobiyal tedavinin 30 günlük mor-
taliteye etkisini değerlendirmek 
Yöntemler: A. baumannii ’nin neden olduğu 87 hastane enfeksiyonlu hasta çalışmaya dahil edildi. Hastalardan 39’unda 
olumlu sonuç alınırken 48 hasta patojen izolasyondan sonraki 30 gün içinde öldü. Antimikrobiyal tedavinin akıbet üze-
rine etkisini değerlendirmek amacıyla, çalışılan gruplardan uygun antimikrobiyal tedavi ile uygunsuz tedavi alan hastalar 
karşılaştırıldı. Kategorik değişkenlerin farklılıklarını değerlendirmek için Ki-kare veya Z-testi kullanıldı. Sürekli değişkenler 
Mann-Whitney testi ile karşılaştırıldı.
Bulgular: Olumlu sonuçları olan hastalardan sadece dört kişi uygun ampirik antibiyotik tedavisi alırken diğer grupta bu 
yalnız üç hastaydı. Odds oranı 1,7 (% 95 CI 0,4-8,2, p=0,77) idi. Temel tedavinin bir parçası olarak uygun antimikrobiyal 
ajanlar uygulanarak tedavi verilen 27 hasta yaşarken, patojen izolasyondan sonra 30 gün içinde 11 hasta öldü. Odds 
oranı 6,7 (% 95 CI 2,6-17,3; p <0.001) idi.
Sonuç: Bizim çalışmamız; nedene yönelik uygun antibiyotik tedavisinin A. baumannii’ye bağlı hastane enfeksiyonları 
olan hastalarda 30 günlük mortalite oranını azalttığını ortaya koymuştur.
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INTRODUCTION
In Europe more than 2 million of hospitalized patients 
acquire nosocomial infections each year, resulting 
in around 175 000 deaths per year.1 Virtually every 
microorganism can cause infection in hospitalized 
patients, but among bacteria Pseudomonas aerugi-
nosa, Enterobacteriaceae spp., Acinetobacter spp., 
Staphylococcus aureus and Enterococcus spp. take 
the leading positions.2-4 A. baumannii (genospecies 
2) has proven to be the most clinically important 
species within the genus.5,6 In the last 20 years A. 
baumannii has grown into a large clinical challenge, 
a fact primarily attributed to common presence of re-
sistance to almost all antimicrobial agents, including 
carbapenems and occasionally polymyxins; and the 
worldwide expansion of hospital areas.7,8 The ability 
of A. baumannii to survive for extended periods on 
dry and wet environmental surfaces is notorious and 
is likely important for circulation and transmission 
within the health care setting.9 The majority of A. 
baumannii -associated infections occur in intensive 
care units (ICU), the others - in oncological, neu-
rosurgical, surgical, haematological and burn de-
partments.6,8,10 It can cause pneumonia (particularly, 
ventilator-associated pneumonia), bloodstream in-
fections, urinary tract infections, skin and soft tissue 
infections, surgical site infections, meningitis, ven-
triculitis, ostheomyelitis, and intraabdominal infec-
tions.6,8,10-12 A. baumannii causes infections mainly 
in severe immunocompromised patients.6,11  The 
typical characteristics of affected patients include 
advanced age, presence of serious underlying dis-
eases, immune suppression, major trauma or born 
injuries, invasive procedures during hospitalization, 
presence of indwelling catheters, performance of 
mechanical ventilation, as well as extended hospital 
stay and previous administration of broad-spectrum 
antibiotics.6 Taking into consideration the above 
mentioned patients’ features it becomes well un-
derstanding that attributable mortality related to this 
microorganism has been difficult to assess. That is 
why, some authors questioned the pathogenicity of 
the microorganism, making in this way discordance 
in the literature regarding the role of A. baumannii 
for lethal outcomes in these patients.13-18
The aim of this study was to assess the impact 
of inappropriate antimicrobial treatment on the 30-
day mortality in patients with A. baumannii -associ-
ated infections.
METHODS
This retrospective study was performed at nine hos-
pitals including seven multi-field hospitals and two 
specialized (Cardiology and Traumatology) medical 
centers located in Minsk (Belarus), whose capaci-
ties vary from 450 to 1050 beds. The study was 
approved by the ethical committee and conducted 
in accordance with its guidelines. Patients were en-
rolled in the study during the two-year period be-
tween December 2008 and November 2010.
All patients at the age of eighteen or older with 
nosocomial infections caused by A. baumannii were 
enrolled in the study. An infection was defined as 
nosocomial if the onset of signs and symptoms 
were on or after the third day of the admission, or 
were present at the admission or became apparent 
before the third day, but the patient had been dis-
charged from a hospital less than thirty days before 
admission. When A. baumannii was consecutively 
isolated as a single pathogen from usually sterile 
sites or from non-sterile clinical material at concen-
tration >105 CFU/ml, a case was considered to be 
etiologically confirmed.
Pathogen identification was performed initially 
in the local microbiological laboratory using VITEK® 
II automated microbial identification system (BioM-
erieux, France) and then confirmed in the reference 
center (Institute of Antimicrobial Chemotherapy, 
Smolensk, Russian Federation) using MALDI-TOF 
(Matrix Assisted Laser Desorption Ionization-Time 
of Flight) Mass Spectrometry method (MALDI Bio-
typer®, Bruker Corporation, USA).
Antimicrobial susceptibility testing was per-
formed by agar-microdilution method. The results 
were interpreted according to the guidelines of the 
Clinical and Laboratory Standards Institute (CLSI, 
USA).19 Intermediately susceptible isolates were re-
garded as resistant. The control strains P. aerugino-
sa ATCC® 27853, E. coli ATCC® 25922 and 35218, 
were tested simultaneously with the studied isolates 
for quality assurance purposes.
The measured outcome was a patient’s death 
within thirty days after A. baumannii isolation from 
the clinical material. In order to assess the antimi-
crobial therapy impact on the outcome the odds ra-
tio model was used. Antimicrobial therapy was con-
sidered to be appropriate, if the set of administered 
antibiotics included at least one antibiotic that was 
active in vitro against isolated strain of A. bauman-
nii and if the route of administration and the dosage 
were appropriate. Empirical antimicrobial therapy 
was defined as administration of antibiotic before 
A. baumannii isolation, while causal antimicrobial 
therapy - as antibiotic administration after A. bau-
mannii isolation.
Data were analyzed using Statistica® software 
v.6.0 (StatSoft Inc., USA). The Chi-squared (χ2) or Gorbich Y, et al. Survival in patients with Acinetobacter baumannii-associated infections 165
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the Z-test was used to assess differences in cat-
egorical variables, as appropriate. Continuous vari-
ables were compared using the Student’s t test or 
the Mann-Whitney test. The Shapiro-Wilk’s test was 
used to assess normality. A two-sided P value of 
less than 0.05 was considered to indicate statistical 
significance.
RESULTS
During the study period, 87 eligible patients were 
identified. The  vast  majority  (77%)  of  them  were 
hospitalized to intensive care units; the others - to 
surgical (13.8%), therapeutical (6.9%) and hemato-
logical (2.3%) departments. Among isolated A. bau-
mannii strains 93.1% were multidrug-resistant (i.e. 
non-susceptible to at least one agent in 3 or more 
antimicrobial categories). A substantial number of 
isolates  were  resistant  to  imipenem  (51.7%)  and 
meropenem (58.6%), sulbactam (34.5%), however 
all studied Acinetobacteria were susceptible to co-
listin.
Among them 39 patients survived or had signif-
icant improvement of their health status (favorable 
outcome) and 48 patients died (unfavorable out-
come) within thirty days after A. baumannii isolation. 
Thus within 30 days after pathogen isolation the 
overall mortality rate among patients with A. bau-
mannii-associated infections included in the study 
was 55.2%. Both groups were comparable in age, 
sex, the weight of ICU-hospitalized patients and the 
proportion of isolated multidrug-resistant (MDR) A. 
baumannii as shown in the Table 1. Patient age dis-
tribution within every studied group is represented 
in the Figure 1.
Variables Favorable outcome 
(n=39)
Unfavorable outcome 
(n=48) p value
Mean ± SD (years old) 50.9 ± 5.6 57.2 ± 3.8 0.06
Gender, Male (%) 25 (64.1%) 35 (72.9%) 0.52
Weight of ICU-hospitalized patients 27 (69.2%) 40 (83.3%) 0.19
Isolation of MDR A. baumannii  35 (89.7%) 46 (95.8%) 0.49
SD=standard deviation; ICU=intensive care unit; MDR=multidrug-resistant
Table 1. Characteris-
tics of the patients with 
nosocomial A. bauman-
nii-associated infections 
according to the out-
comes on Day 30 after 
pathogen isolation
Among patients with favorable outcomes, 4 
persons (10.3%) received appropriate empirical an-
timicrobial treatment, while in the other group - only 
3 patients (6.3%). The odds ratio was 1.7 (95% con-
fidence interval (CI), 0.4-8.2) but the difference was 
not significant (p = 0.77).
At the same time, appropriate antimicrobial 
agents were administered as a part of causal treat-
ment to 27 patients (69.2%) who survived and to 
11 patients (22.9%) who died within 30 days after 
pathogen isolation. The odds ratio was 6.7 (95% CI 
2.6-17.3), the difference reached statistical signifi-
cance (p<0.001).
Favorable outcome  Unfavorable outcome
 (n=39)  (n=48)
Fig 1. Age distribution 
of the patients with 
nosocomial  Acineto-
bacter baumannii-
associated infections 
within studied groups.Gorbich Y, et al. Survival in patients with Acinetobacter baumannii-associated infections 166
J Microbiol Infect Dis   www.jmidonline.org   Vol 3, No 4, December 2013
DISCUSSION
The main finding of this study is that administration 
of  inappropriate  antimicrobial  therapy  significant-
ly increases the 30-day mortality rate in patients 
with A. baumannii-associated infections. Based on 
these data, it is clear that A. baumannii contributes 
to increased mortality rate. Thus, the results of the 
present study confirm that A. baumannii is a real 
pathogen and infections caused by this microorgan-
ism are associated with increased mortality. In ac-
cordance with our findings, Joung et al. confirmed 
that  inappropriate  definitive  antimicrobial  therapy 
(odds ratio (OR) 3.05; 95% CI: 1.05-8.86; P=0.04) 
and Acute Physiology and Chronic Health Evalu-
ation (APACHE) II score ≥20 (OR 4.27; 95% CI: 
1.57-11.64; P=0.005) were independent factors as-
sociated with a high mortality in 116 patients with 
clinically significant Acinetobacter hospital acquired 
pneumonia 20). In the other study performed by the 
authors from China APACHE II score >20 at disease 
onset (OR 3.02; 95%CI: 1.3-7.0; P=0.01), presence 
of  chronic  respiratory  disease  (OR  3.17;  95%CI: 
1.38-7.28: P=0.01), infections with additional patho-
gen (OR 9.01; 95%CI: 4.0-21.02; P<0.001), and in-
appropriate antibiotic treatment (OR 6.92; 95%CI: 
2.95-16.22:  P<0.001)  were  independently  associ-
ated with 28-day mortality in patients with nosoco-
mial pneumonia caused by carbapenem-resistant 
A. baumannii.21 Lee et al. reported that appropriate 
antimicrobial therapy was independently associ-
ated with reduced mortality in patients with A. bau-
mannii bacteremia (OR 0.22; 95% CI, 0.01-0.50; P 
<0.001), but the benefit of appropriate therapy was 
limited to patients with high APACHE II scores (OR 
for patients with scores >25 and ≤ 35, 0.16; 95% 
CI, 0.07-0.37; OR for those with scores >35, 0.06; 
95% CI, 0.01-0.25) 22. In Thailand a retrospective 
study of 110 patients with carbapenem-resistant A. 
baumannii nosocomial infections demonstrated that 
renal impairment, bloodstream infection, and inap-
propriate antimicrobial regimen were independent 
predictors of treatment failure and poor treatment 
outcomes.23 It is important to note that according to 
the data from some clinical studies, resistance to 
carbapenems by itself has no impact on mortality 
rates in patients with A. baumannii infections.24-26 
And finally, a systematic review of matched case-
control and cohort studies examining the mortality 
that is attributable to infection or colonization with 
A. baumannii revealed that statistically significant 
higher mortality was associated with A. baumannii 
infection or colonization.16 In the hospital and in the 
intensive care units the attributable mortalities of pa-
tients with A. baumannii infection ranged from 7.8% 
to 23% and from 10% to 43% respectively.9,16,17
However, Eberly et al. stated that A. baumannii 
infection, including multidrug-resistant strains, has 
inconclusive impact on mortality in a cohort of trau-
ma patients. The in-hospital mortality was higher in 
the pathogen group (16% vs. 13%; p=0.67), but the 
difference was not significant. At the same time A. 
baumannii infection was associated with a longer 
intensive care unit stay (median, (range), 28 (7-181) 
days vs. 17 (2-130) days, respectively; p=0.05) and 
a higher rate of ARDS and acute liver failure (35% 
vs. 15%; p = 0.02 and 26% vs. 10%; p = 0.04) when 
compared to controls.13 In Belgian retrospective 
matched cohort study in critically ill patients A. bau-
mannii bacteremia was associated only with more 
severe hemodynamic instability, longer ICU stay, 
and longer length of ventilator dependence, but not 
associated with a significantly increased mortality 
rate (42.2% vs. 34.4% when compared to control 
group).15
On the contrary to some other studies, we did 
not confirm the influence of inappropriate empirical 
therapy on clinical outcomes in those patients.18,27,28 
Erbay et al. reported that significant independent 
risk factors for mortality in patients with A. bauman-
nii bacteremia were delayed appropriate treatment 
(hazard ratio (HR)=2.4, 95% CI)1.3-4.2; p=0.004), 
development of septic shock (HR=2.6, 95% CI 1.4-
4.8; p=0.004), age>65 years (HR=2.1, 95% CI 1.2-
3.7; p=0.007) and mechanical ventilation (HR=3.3, 
95%  CI  1.5-7.4;  p=0.003)  18.  In  the  other  study 
performed by Taiwan authors prolonged ventila-
tion days (odds ratio=3.4; 95% CI 1.7-6.1; p=0.01) 
and inappropriate empiric antibiotic therapy within 
48 hours (odds ratio=7.9; 95% CI: 3.9-9.8; p=0.02) 
were independent factors that predicted the 30-day 
mortality from nosocomial A. baumannii infections 
in chronically ventilated patients.27 In their study 
Lee et al. found that the 30-day crude mortality rate 
was higher among patients received inappropriate 
empirical antimicrobial therapy than it was among 
patients initially treated by appropriate (in vitro ac-
tive) antibiotic regimens (32/63, 50.8% vs. 21/67, 
31.3%; p=0.032). Another interesting finding from 
their study was observation that the patients with 
empirical combination therapy had a lower mortality 
rate (adjusted odds ratio 0.31; 95% CI: 0.15-0.72; 
p=0.006).28
Reported in our research overall mortality rate 
of 55.2% is rather high but it correlates with the data 
received from other studies. The crude mortality 
rate in patients with A. baumannii-associated in-Gorbich Y, et al. Survival in patients with Acinetobacter baumannii-associated infections 167
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fections varies from 14% to 60% depending on the 
study.8,29-31
This study has limitations and strengths. The 
limitations include a small sample size and retro-
spective design. The strengths include the accurate 
pathogen  identification  using  MALDI-TOF-mass-
spectrometry  method,  and  the  clear  definition  of 
nosocomial origin of infection in the included pa-
tients based on clinical interpretation of every case.
In conclusion, we have found out that inap-
propriate antimicrobial therapy increased 30-day 
mortality rate in patients with nosocomial infections 
caused by A. baumannii, thus confirming the state-
ment that A. baumannii is a real pathogen but not a 
witness of the lethal outcome. Taking into consider-
ation, that the majority of hospital isolates of A. bau-
mannii was multidrug-resistant and also the differ-
ences in the pathogen resistance phenotypes be-
tween different countries, cities and even hospitals, 
it is crucial for adequate anti-Acinetobacter therapy 
to use local clinical and microbiological data.
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